Study to Evaluate the Safety, PK, PD, and Efficacy of PRX-102 in Japanese Patients With Fabry Disease
NCT05710692
·
clinicaltrials.gov ↗
PHASE2,PHASE3
Phase
RECRUITING
Status
16
Enrollment
INDUSTRY
Sponsor class
Conditions
Fabry Disease
Interventions
DRUG:
PRX-102 1 mg/kg every 2 weeks
DRUG:
PRX-102 2 mg/kg every 4 weeks
Sponsor
Chiesi Farmaceutici S.p.A.
Collaborators
[object Object]